Jazz Pharmaceuticals, Inc.

JAZZNASDAQUSD
256.65 USD
4.92 (1.88%)AT CLOSE (11:59 AM EDT)
254.00
2.65 (1.03%)
POST MARKET (AS OF 07:34 PM EDT)
Post Market
AS OF 07:34 PM EDT
254.00
2.65 (1.03%)
🔴Market: CLOSED

JAZZ is currently priced at $256.91. The stock presents a bullish profile across the board: both technical indicators and our fundamental models signal a "Strong Buy" and "Buy" respectively. This is driven by a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, JAZZ trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Aug 6, 2026.

Open?$262.44
High?$264.03
Low?$255.69
Prev. Close?$261.57
Volume?833.9K
Avg. Volume?797.7K
VWAP?$258.68
Rel. Volume?1.05x
Bid / Ask
Bid?$242.39 × 100
Ask?$270.89 × 100
Spread?$28.50
Midpoint?$256.64
Valuation & Ratios
Market Cap?17.0B
Shares Out?62.8M
Float?60.2M
Float %?95.8%
P/E Ratio?18.05
P/B Ratio?3.54
EPS?$14.49
Dividend?0.00%
Ex-Dividend?N/A
RelatedAXSM
News
Profile
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Employees
2.9K
Market Cap
17.0B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2007-06-01
Address
FIFTH FLOOR, WATERLOO EXCHANGE
DUBLIN, D04 E5W7
Phone: 353-1-634-7800
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+3/3)
Medium-Term (Wave)? Bullish(+2/3)
Short-Term (Ripple)? Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?
77
Z-Score?
57
Momentum?
69
Short Sent.?
64
Piotroski F-Score?6/9Mixed
Altman Z-Score?2.60Grey
Confidence?81%High
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?6.32%Elevated
Short Interest?3.8M
Days to Cover?4.8
Free Float60.2M
Avg Daily Volume786.6K
Settlement Date2026-07-15
Financial Health
Current Ratio?1.78Adequate
Quick Ratio?1.58Adequate
Cash Ratio?0.73Adequate
Debt/Equity?0.91Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
72/100
P/E?
S&P
71
18.1FAIR
P/B?
Peers
100
S&P
49
3.54FAIR
P/S?
Peers
100
S&P
41
3.69FAIR
P/FCF?
S&P
85
11.2CHEAP
EV/EBITDA?
S&P
67
12.2FAIR
EV/Sales?
Peers
100
S&P
43
4.28FAIR
Returns & Efficiency
ROE?
S&P
65
19.6%STRONG
ROA?
S&P
68
8.5%STRONG
Cash Flow & Enterprise
FCF?$1.5B
Enterprise Value?$19.7B
Fundamentals ratios updated end of day